To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Clinical trial NCT05442060 · RECRUITING
Trial details
- NCT number
- NCT05442060
- Sponsor
- OBI Pharma, Inc
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-27
- Primary completion
- 2025-12-31
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.